The Global Oligonucleotide API Market was valued at USD 2.48 Billion in 2025 and is projected to reach USD 5.83 Billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 12.7% during the forecast period. This growth is being driven by rising demand for targeted therapies in oncology and rare genetic diseases, expanding applications in precision medicine, and significant advancements in oligonucleotide synthesis technologies.

As the biopharmaceutical industry shifts toward gene-specific treatments and personalized healthcare solutions, the spotlight is on the key players who are driving innovation, scalable manufacturing, and regulatory excellence in oligonucleotide active pharmaceutical ingredients. In this blog, we profile the Top 10 Companies in the Oligonucleotide API Industry—a mix of pioneering therapeutics developers, specialized manufacturers, and contract development organizations shaping the future of nucleic acid-based medicines.

---

🔟 1. Alnylam Pharmaceuticals

Headquarters: Cambridge, Massachusetts, USA
Key Offering: siRNA-based Oligonucleotide APIs

Alnylam Pharmaceuticals stands as a global leader in RNA interference (RNAi) therapeutics, developing and commercializing innovative oligonucleotide APIs that silence disease-causing genes. The company has successfully brought multiple siRNA therapies to market, serving patients with rare genetic disorders and expanding into broader therapeutic areas through its proprietary platform.

Innovation Initiatives:

• Advancing GalNAc conjugation technology for targeted liver delivery

• Robust pipeline of RNAi therapeutics across multiple indications

• Strategic partnerships with leading pharmaceutical companies

Download FREE Sample Report: Global Oligonucleotide API Market – View in Detailed Research Report

---

9️⃣ 2. Ionis Pharmaceuticals

Headquarters: Carlsbad, California, USA
Key Offering: Antisense Oligonucleotide APIs

Ionis Pharmaceuticals is a pioneer in antisense technology, with a proven track record of discovering and developing oligonucleotide APIs that modulate RNA to treat severe diseases. Through collaborations with major pharmaceutical firms, the company has multiple approved therapies and a deep pipeline focused on neurological, cardiovascular, and rare diseases.

Innovation Initiatives:

• Development of next-generation antisense chemistries

• Expansion into new therapeutic modalities and delivery systems

• Focus on high-specificity oligonucleotides with improved safety profiles

---

8️⃣ 3. Sarepta Therapeutics

Headquarters: Cambridge, Massachusetts, USA
Key Offering: Antisense Oligonucleotide APIs for Duchenne Muscular Dystrophy

Sarepta Therapeutics specializes in precision genetic medicines, particularly exon-skipping antisense oligonucleotides designed to treat rare neuromuscular disorders. The company has established itself as a key player through its innovative approaches to restoring dystrophin production in patients with Duchenne muscular dystrophy.

Innovation Initiatives:

• Advancement of PPMO (peptide-conjugated) technology platforms

• Expansion of exon-skipping candidates for additional patient populations

---

7️⃣ 4. Nitto Denko Avecia

Headquarters: Cincinnati, Ohio, USA (Nitto Denko Corporation, Japan)
Key Offering: Custom Oligonucleotide API Manufacturing Services

Nitto Denko Avecia is one of the world’s largest and most experienced contract manufacturers of oligonucleotide APIs, providing end-to-end services from process development to commercial-scale production. The company supports both clinical and commercial needs with state-of-the-art facilities and rigorous quality standards.

Innovation Initiatives:

• Investment in large-scale synthesis and purification technologies

• Development of efficient manufacturing processes for complex sequences

• Support for modified and conjugated oligonucleotides

Download FREE Sample Report: Global Oligonucleotide API Market – View in Detailed Research Report

---

6️⃣ 5. Ajinomoto Bio-Pharma Services

Headquarters: Osaka, Japan (with global operations)
Key Offering: Oligonucleotide API Development and Manufacturing

Ajinomoto Bio-Pharma Services, through its GeneDesign acquisition, offers comprehensive oligonucleotide API services including synthesis, modification, and GMP manufacturing. The company is recognized for its expertise in producing high-quality nucleic acid-based APIs for therapeutic and research applications.

Innovation Initiatives:

• Focus on scalable enzymatic and chemical synthesis methods

• Expansion of capacity to meet growing global demand

---

5️⃣ 6. Jazz Pharmaceuticals

Headquarters: Dublin, Ireland
Key Offering: Oligonucleotide APIs for Neurological and Oncology Applications

Jazz Pharmaceuticals has strengthened its presence in the oligonucleotide space through strategic acquisitions and internal development, focusing on APIs that address critical unmet needs in rare diseases and hematology/oncology. The company integrates oligonucleotide technology into its broader neuroscience and oncology portfolio.

Innovation Initiatives:

• Investment in manufacturing infrastructure and capacity expansion

• Collaborations to advance novel oligonucleotide candidates

---

4️⃣ 7. Biogen

Headquarters: Cambridge, Massachusetts, USA
Key Offering: Antisense Oligonucleotide APIs

Biogen has been at the forefront of developing antisense oligonucleotide therapies, particularly for neurological disorders. Through partnerships with leaders like Ionis, the company has successfully commercialized treatments that target specific genetic mechanisms underlying neurodegenerative diseases.

Innovation Initiatives:

• Advancement of intrathecally delivered oligonucleotide therapies

• Research into broader applications in CNS disorders

---

3️⃣ 8. Dynavax Technologies

Headquarters: Emeryville, California, USA
Key Offering: CpG Oligonucleotide APIs for Immunotherapy

Dynavax Technologies develops CpG oligonucleotides that act as immune modulators, enhancing the body’s response to vaccines and immunotherapies. The company’s proprietary technology platform supports applications in infectious diseases and oncology.

Innovation Initiatives:

• Development of novel adjuvant formulations

• Expansion into combination therapies with checkpoint inhibitors

---

2️⃣ 9. ST Pharm Co., Ltd.

Headquarters: Seoul, South Korea
Key Offering: Oligonucleotide API Contract Manufacturing

ST Pharm is a leading Asian contract manufacturer specializing in oligonucleotide APIs, offering high-quality synthesis and scale-up services to global biopharmaceutical clients. The company has invested heavily in GMP-compliant facilities to support clinical and commercial production.

Innovation Initiatives:

• Enhancement of cost-efficient manufacturing processes

• Capacity expansion to serve international markets

---

1️⃣ 10. RiboBio Co., Ltd.

Headquarters: Guangzhou, China
Key Offering: siRNA and Custom Oligonucleotide APIs

RiboBio is a prominent Chinese biotechnology company focused on RNA-based therapeutics and oligonucleotide API production. The firm provides research tools, custom synthesis, and development services while advancing its own pipeline of siRNA candidates.

Innovation Initiatives:

• Development of RNAi therapeutics for oncology and metabolic diseases

• Investment in advanced synthesis and delivery technologies

Get Full Report Here: Global Oligonucleotide API Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Oligonucleotide API Is Targeted and Transformative

The oligonucleotide API market is experiencing robust expansion as nucleic acid-based medicines move from niche applications to mainstream therapeutic options. While challenges in manufacturing scale and regulatory pathways remain, the industry continues to invest in innovative synthesis methods, improved delivery systems, and expanded production capacity.

📈 Key Trends Shaping the Market:

• Rapid growth in siRNA and antisense oligonucleotide pipelines

• Increasing reliance on specialized CDMOs for commercial manufacturing

• Advancements in chemical modifications for enhanced stability and specificity

• Geographic expansion of manufacturing capabilities in Asia-Pacific

Get Full Report Here: Global Oligonucleotide API Market – View in Detailed Research Report

The companies listed above are not only supplying critical active pharmaceutical ingredients—they are enabling the next generation of precision medicines that target diseases at their genetic roots.